Given these conditions, it should come as no surprise that “branding” is more important than ever. Yet many firms struggle with the vast number of opinions as to the definition of branding and the debate about why, how, and when to go about the process of branding the firm.

This article seeks to ground the conversation by answering the fundamental questions “What is a brand really about?” and “Why is it important to brand a law firm?”

Ultimately the PTO sided with i4i and confirmed the validity of its patent.  The PTO issued A Notice of Intent to Issue a Reexamination Certificate (NIRC) on April 28, 2010; the  Reexamination Certificate being issued today, July 27, 2010 in the eOfficial Gazette for Patents.  The Reexamination Certification is the final step in the patent reexamination.  Microsoft may not appeal the PTO's decision.

i4i was represented by Sterne, Kessler, Goldstein & Fox, led by attorneys Robert Greene Sterne, Lori A. Gordon, and Robert W. Molitors. 

• Preventing delays due to failure to engage - understanding how the PTO defines "failure to engage"
• What constitutes late filing under the PTO's PTA rules? - identifying triggers for action date, defining action date and filing provisions (37 CFR 1.6;1.8 and 1.10)- Which stops clock and which does not?
• Circumventing PTO findings of an incomplete reply - what is considered non-responsive and non-complaint?
• Explaining delay concerns associated with supplemental replay and information disclosure statements
• Terminal disclaimers- defining them and avoiding them

Other presentation topics include:

• How generic companies will implement the now-approved follow-on biologic pathway, including what is patentable, exclusivity, and patent resolution
• How to draft and protect claims going forward in light of the attacks on the patentability of genes and diagnostic methods in Bilski and Myriad
• Advanced claim drafting strategies and how to incorporate both the written description and enablement requirements
• Avoiding inequitable conduct- lessons from Therasense, Inc. v. Becton, Dickinson & Co.
• How to work the PTO rules and the patent prosecution highway in order to streamline the patent approval process and extend actual patent life
• Developing global strategies for minimizing risk and maximizing profit while filing and protecting patents abroad.

Click here for more information about this conference.

Each Sendona Conference features a 15-person faculty bringing together the finest attorneys, jurists and academics in the nation currently confronting cutting-edge issues, and the participant base is limited to no more than 45 additional, experienced attorneys and others to ensure the opportunity for meaningful dialogue. Find additional information about this conference here.  

• The importance of biosimilars to the biologics industry,
• Alternative proposals that were rejected during the legislative process,
• The significance of the 12-year exclusivity provision and the idea that its relative length will aid innovation in the industry, and
• The likely impact of the biosimilars pathway on the biopharmaceutical sector.

After offering a broad perspective on the legislation, our program faculty will analyze the impact of the biosimilars pathway on patent licensing. The new legislation had important ramifications for patent licensing, including:

• Increased significance of process/platform IP in the biopharmaceutical industry,
• The potential for forfeiture of rights for exclusive licensors due to the failure of a licensee to properly execute the patent dispute procedures of the biosimilars statute,
• The diverging interests of licensors and licensees under the statute, and
• The need to draft new licenses (and amend existing licenses) to account for the new statute.

Click here for more information about this webinar.

 International Bioenergy Days provides an excellent opportunity for learning the latest advances in the field.

• This meeting will provide opportunities to make contacts that will help you create value and new jobs.
• This is the place where managers, entrepreneurs and decision-makers from the US, Sweden, and the rest of Europe will meet to pursue their common interest to turn bioenergy technology into concrete business opportunities.
• The conference will also highlight alternative energy in the Great Lakes region through special exhibits and tours.

For more information or to register for this event, click here.

The format of the program will be a panel discussion.  MdBio has confirmed Dr. Philip Huang, Senior Director of Regulatory Affairs and Special Projects at Merck Research Laboratories and Timothy Shea from Sterne Kessler to discuss IP and licensing issues, and is pursuing invitations with other and industry experts.  Dr. Kadriye Ciftci, Sr. Director of Regulatory Affairs at ICON Clinical Research, will be the program moderator.

This will be a joint presentation in which Dr. L. R. Mullin (SUNY,Albany) will discuss the new mathematical theorem and Dr. Raynolds will discuss numerical computational experiments and results.

The emphasis of the review is on the eight CLP domains, the practice exam questions and the participant’s results. Three experienced LES members that have achieved CLP™ status present the one-day, face-to-face course. Each one-hour webinar provides another opportunity for the test registrants to review the domains and to ask questions of the LES experts.

Click here to see the full program schedule or to register.

This presentation will be repeated on August 10, 2010.

Discussion topics:
1. Best practices for building IP.
2. Conducting due diligence investigations.
3. Presenting IP information in a way that best positions that company to its prospective partner.

Through the prism of series of recent transaction examples, the workshop will discuss what worked well and why, as well as mistakes that could have been avoided. Therefore, this workshop would be of keen interest to companies currently involved or contemplating entering into a partnering deal, as well the investment community. Click here for more information about this event.

Discussion points will include:

• Reevaluating existing licenses to determine the practical and financial impact of follow-ons on the license agreement
• Determining the correct course of action should a university want a patent enforced
• Identifying who has discretion in deciding which products will be launched
• Specific clauses and terms to include in agreements to account for follow-ons
• How do follow-ons impact valuation of products and deals and potential revenue streams

Through a series of recent decisions, the Federal Circuit has demonstrated that it will vigorously scrutinize the basis for patent damages awards. All parties involved in patent litigation will benefit from a deeper understanding of the analytical framework used by the Federal Circuit to review patent damages awards.

This webinar will discuss the current framework for patent damages resulting from the Federal Circuit's interpretation of the landmark Georgia-Pacific decision. Three important recent Federal Circuit decisions, Lucent Technologies, Inc. v. Gateway, Inc., 580 F.3d 1301 (Fed. Cir. 2009), i4i Ltd. v. Microsoft Corp., 589 F.3d 1246 (Fed. Cir. 2009), and ResQNet.com, Inc. v. Lansa, Inc., 2010 U.S. App. LEXIS 2453 (Fed. Cir. 2010), demonstrate that there has been a shift in the Federal Circuit's scrutiny of damages awards. These decisions provide discrete lessons for both patent plaintiffs and patent defendants and will be discussed in detail in the webinar.

Robert Greene Sterne will give the keynote speech on "The Impact of the U.S. Reexamination Process on Patent Portfolio Value."

The Bright Lights Conference will showcase 50 of the most innovative public companies ranked in the 90th percentile for technology leadership.  These companies were selected from more than 1,600 small cap companies which were scored, ranked and analyzed on the basis of their rate of innovative change, as well as the novelty, quality and industry impact of their patents.

Listen to the keynote address by downloading the audio. 

The Bright Lights Conference will showcase 50 of the most innovative public companies ranked in the 90th percentile for technology leadership.  These companies were selected from more than 1,600 small cap companies which were scored, ranked and analyzed on the basis of their rate of innovative change, as well as the novelty, quality and industry impact of their patents.

For more information, or to register for the conference, click here.

Kevin W. McCabe will  speak on April 27th at 2:00pm on  the topic of Pleadings and Considerations.

To read more about the conference or to see the full agenda click here.

Their hour long presentation will include an initial discussion on the topic of  patent reexamination and concurrent patent litigation strategies — one of the most important and rapidly developing topics in patent enforcement in the United States — and conclude with a lively question and answer session.

Their hour long presentation will include an initial discussion on the topic of  patent reexamination and concurrent patent litigation strategies — one of the most important and rapidly developing topics in patent enforcement in the United States — and conclude with a lively question and answer session.

The team spoke to an engaged audience of George Mason intellectual property students and other outside attendees.  Sterne and Wright's hour-long discussion focused on the rapidly developing area of patent reexamination within the United States.  The talk's material was taken from Sterne and Wright's ongoing reexam cases, as well as their roles in authoring Reexamination Practice with Concurrent District Court Litigation or Section 337 USITC Investigations, a go-to guide on reexams, published by The Sedona Conference. 

The presentation concluded in a question and answer session with the audience.  Students and attendees asked pointed questions to Sterne and Wright about current reexam cases, SKGF's micro website www.reexamcenter.com, and the future impact of patent reexamination in intellectual property law.  Jon Wright, a George Mason Law alumni, commented that "it was great to get back to my alma mater, George Mason, and talk to the current students.  They were engaged through the whole presentation and threw us some very astute questions at the end.  Rob and I appreciated their energy and we wish we could have stayed a bit longer." 

The Course Covers:

• IP Basics: patents, trademarks, know-how, trade secrets and more

• Smart strategies for creating, organizing, managing and securing IP assets

• Commercialization — Bringing IP to market

• Royalties and ideas for maximizing IP value and making money!

• A licensing game with an interactive deal negotiation — a hands-on opportunity for you!

Click here to register. 

Through a series of presentations and panels, participants will increase their knowledge of: the decision-making process at the Board, how to avoid mistakes commonly made when appearing before the Board, how to properly and persuasively present evidence by way of affidavits and the inter partes reexamination process. Participants will also hear from Chief Judge Paul R. Michel and Circuit Judge Randall R. Rader of the U.S. Court of Appeals for the Federal Circuit on the role of the Board in the development and advancement of the patent system.

We will be sponsoring a reception in the lower atrium, immediately following the BPAI conference.

 The two hour long presentation was divided into two parts.  The first half of the program focused on the topic of  patent reexamination and concurrent patent litigation strategies.   The second half zeroed in on alternative career paths and how students can stand out in the recruiting process during a down economy.

 When asked about returning to his Alma Mater (The University of Maryland School of Law ’77), Mr. Sterne commented, "it was touching and special to be back at the Law School.  It was a real honor to have the opportunity to speak on such a hot topic as reexaminations to a classroom of such bright students.  What a smart group of students and what a fantastic law school!  Made me feel so proud to see the school carrying on the tradition of turning out quality attorneys!"

The presentation was facilitated by Benjamin Huh (Co-President) and Bruce Villard (Treasurer) of the Law School of Maryland Intellectual Property Student Association (MIPSA) in conjunction with Patricia Campbell, Associate Professor and Director, Maryland Intellectual Property Legal Resource Center.

This program will begin at 9:00 a.m. and is an opportunity for managers, design examiners and the design patent bar to exchange ideas and to educate each other on important topics affecting design patent practice. Topics for discussion include the integration of aesthetics, commercial appeal and intellectual property considerations into product design, the role of the USPTO Solicitor’s Office in design patent practice, litigating design cases in US District Courts, and the recent decisions in Seaway Trading Corp. v. Walgreens Corp, Crocs v. ITC, and Richardson v. Stanley Works. 

The program is open to all and there is no fee. However, for planning purposes pre-registration is encouraged and can be done on-line at http://www.aipla.org/.

For the event day agenda, click here.

The Technology Managers for Global Health serves as a share-and-learn platform to:

1. Encourage licensing policies, partnering/negotiation strategies, and invention management practices that address humanitarian concerns (e.g., assuring fair access for new technologies that address treatments for neglected tropical diseases and other afflictions widely prevalent among the world's poorer populations); 
2. Feature individuals, programs, and case studies representing the evolving contexts within which academic innovation management frameworks [delete-need to be] creatively design[ed] and thougtfully implement[ed] such policies to address, for example, the [in a] complex and dynamic field of [such as] global health; and
3. Improve understanding of the ongoing challenges and opportunities of being engaged in transnational and multi-sector initiatives aimed at advancing global health causes.

Please visit www.tmgh.org for further information.

Rob Sterne and Lori Gordon Present at GWU March 17, 2010 (Image Courtesy of George Washington University Law School)

Their hour long presentation included an initial discussion on the topic of  patent reexamination and concurrent patent litigation strategies — one of the most important and rapidly developing topics in patent enforcement in the United States — and concluded with a lively question and answer session.

Associate Dean for Intellectual Property Law Studies John Whealan (former Solicitor of the USPTO and staffer to the Senate Judiciary Committee) was in attendance and asked questions relating to the time it takes to complete a reexamination (especially inter partes) and the quality of reexamination with regard to the recent ramp up in filings.  The seminar was well received and built on a similar presentation made by Rob Sterne to the GWU students in 2009.

Prof. Sam Oddi, of Akron, will moderate a panel discussion on patentable subject matter and Bilski.  Panelists are Prof. Osenga, Prof. Carl Moy, Mike Dzwonczyk, and SKGF's Robert Greene Sterne.

To see the full conference agenda or to register click here.

• Update on progress of biosimilars legislation through the U.S. House
  and Senate
• Analysis of the provisions of the competing U.S. bills
• Comparison of the proposed biosimilars legislation to small molecule regulation under Hatch-Waxman
• Views of affected constituencies (biopharma companies, generics companies, health care providers, patients)
• Comparison of the proposed US regulatory scheme to those in other parts of the world (especially Europe and Japan)

• How innovative companies can overcome two major obstacles:
  • Create and protect technologies that are both functionally and economically feasible particularly in industries with a low profit margin like the biofuel industry
  • Navigate relevant technology patents that are issued or pending
• Explore steps that emerging biofuel and other cleantech companies must take in order to avoid the kind of patent problems that have plagued and ultimately destroyed many new innovative companies

In light of the Supreme Court's Quanta v. LG decision, is it possible to avoid patent exhaustion when licensing IP?  Mr. Lee will present on the topics of licensing and patenting approaches including the effect of covenants not to sue.   James J. Kulbaski of Oblon, Spivak, McClelland, Maier & Neustadt, L.L.P., will also be presenting on the issues of using a patent trust with respect to MPEG LA v Multimedia Patent Trust.

For more information including a full schedule of events and directions click here.

THE SEDONA CONFERENCE® "VOICES FROM THE DESERT" WEBINAR SERIES PRESENTS THE PATENT REFORM WEBINAR - WEDNESDAY, DECEMBER 16, 2009 AT 2:00 PM EASTERN

While generating less-widespread attention than other proposals before Congress, the pending patent reform legislation has produced huge debate and concern in the patent community. The faculty from the recent Tenth Annual Sedona Conference® on Patent Litigation wants to share its best thinking on three key areas in which fundamental changes have been proposed: (1) willfulness; (2) post-grant review and expanded inter partes reexamination; and (3) first to file.

Our annual conference on patent litigation (like our other regular season conferences) is strictly limited to 45 participants so we have decided to provide webinars on various issues discussed to bring the benefit of the collective wisdom generated to the broader Bench and Bar. We chose the topic of patent reform legislation to be the first topic from this year's patent litigation conference because some are of the opinion that a form of legislation may actually pass early in 2010, so now is the time for those interested to get up to speed on the potential changes that may come to both patent prosecution and patent litigation.

Thus, the webinar will address the following:

Agenda:

2:00 - 2:50 EST

*Proposed changes with regard to the law on willfulness;

*Proposed changes with regard to the law on post-grant review and expanded inter partes reexamination

*Proposed changes with regard to the law on invention date (elimination of the "first to file" rule)

2:50 - 3:00 EST Question-and-comment session

This webinar will be moderated by Richard G. Braman (Executive Director, The Sedona Conference®) and includes a distinguished panel featuring the Honorable Chief Judge Paul R. Michel (U.S. Court of Appeals for the Federal Circuit, Washington, DC), Maximilian A. Grant (Latham & Watkins, Washington, DC), Rachel Krevans (Morrison & Foerster, San Francisco, CA), and Robert G. Sterne (Sterne Kessler Goldstein & Fox, Washington, DC).

• Exploring methods for obtaining an order to pursue discovery in various jurisdictions
• Evaluating what forms of discovery are available in the jurisdiction in which you are litigating
  • civil law vs. common law
  • interrogation and cross examination
  • seizures vs. preservation of evidence
• Seeking discovery on the basis of a foreign pharmaceutical patent
  • working around unique issues that may arise when pursuing discovery of information only attainable from a non-U.S. office or employee
  • complying with various local and country-specific requirements when seeking discovery of information in various jurisdictions
• Becoming familiar with foreign discovery timetables
• Maintaining a reasonable discovery budget
• Determining whether or not evidence obtained in one country can be:
  • used to pursue discovery in another country
  • used as evidence in a parallel or separate but related suit in another country

To see the full conference agenda, click here.

The Conference will be held at LUISS (Libra Universita Instituto Science Sociale) Guido Carli- a private Social Sciences University in Rome.

• Establishing your witness as an expert skilled in the art
  • drawing attention to the expert’s experience developing and dealing with the type of product at issue
  • stressing the expert’s reputation in the industry as a well-respected leader
• Getting the witness to distinguish the inventive nature of the product by highlighting the non-obvious nature of the invention to one of ordinary skill in the art
• Exploring and dispelling the signifi cance of all prior art – demonstrating through the NDA record how the patentee overcame stumbling blocks to ultimately secure drug approval
• Anticipating the opposition’s cross examination by showing that the science underlying the patent is valid, unique and non-obvious

To learn more about the event, click here.

During this session, patent litigators experienced in representing both brand name and generic manufacturers will discuss proven strategies for preparing for your next paragraph IV case. Topics of discussion will include:

• Evaluating triggering events that ultimately effect the timing of the lawsuit
  • strength of patents – what patents to assert and what patents to challenge?
  •  discussing fi ling strategies – identifying and evaluating the criteria for deciding where to bring suit
• Multiple ANDA filers – dealing with and positioning yourself as one of several ANDA filers
• Witness and expert selection
  • identifying key points on which the opinion of an expert will be sought by both sides
  • locking up the right experts in advance of fi ling
• Scope of discovery
  • what to exclude, what to allow, what to ask for
  • at what point is a discovery request over burdensome?
• Summary Judgment
  • strategy considerations
  • selecting the right (and ripe) issues
• Markman Hearing and claim construction
  • assessing whether Markman hearings should take place before or after expert reports and discovery
  • arguing disputed claims before the judge – what to argue and what to save for trial
• Weighing the pros and cons of agreeing to a judge’s tutorial

To learn more about the conference, click here.

• How innovative companies can overcome two major obstacles:
  • Create and protect technologies that are both functionally and economically feasible particularly in industries with a low profit margin like the biofuel industry
  • Navigate relevant technology patents that are issued or pending
• Explore steps that emerging biofuel and other cleantech companies must take in order to avoid the kind of patent problems that have plagued and ultimately destroyed many new innovative companies

Patents provide owners with monopoly rights to exclude.  This provides an artificial barrier to competition.  How that barrier is constructed and maintained greatly defines a company's ability to protect its market share.  This talk will explore the steps that companies must take in order to develop a strategic patent portfolio and the benefits derived from such, including increased market revenue and share, increased brand recognition, and the potential for licensing revenue.

To learn more about the conference, click here.

To see the full conference schedule, click here and for more info on the presentation, click here.

1. Re-exam and Litigation
2. Obviousness
3. Inequitable Conduct
4. Injunctive Relief & Damages for Future Infringement
5. Reasonable Royalties
6. Process Forum: Local Rules Developments and Model CMO's
7. Extraordinary Relief
8. Patent Reform Legislation Update

To learn more about the meeting, click here.

To learn more about the meeting, click here.

• Extension of patent term under 35 U.S.C. § 156 and 37 CFR 1.710 – 1.791
• Exploring the viability of extension applications to:
  • basic and combination compounds; secondary patents
• Important benchmarks in the drug’s developmen tand patent timelines
• Eligibility for patent term extension
• Regulatory review period determinations
• How to calculate the patent term restored
  • respective roles of the FDA and the PTO in granting patent extensions
  • third-party challenges – “diligence”
• Patent term extensions outside the U.S.
• Examining patent term adjustment due to delays in prosecution before the USPTO
  • strategies for:
    • diligence in prosecution by the patent applicant
    • calculating the adjustment period
• Understanding the link between patent extensions and exclusivity
  • extensions obtained through FDA Pediatric Exclusivity and Orphan Drug Exclusivity
• Obtaining patent coverage for pharmaceuticals through the use of second-generation patents, e.g.,
  • maintaining patent position for second-generation products
  • approaches taken by pharmaceutical companies in obtaining second-generation patents
  • enforcement of second-generation patents
• Assessing the impact of the PTO Rule regarding elimination of continuation practice on pharmaceutical patent extensions

Patent reform, the new administration, evolving case law, and the current economic climate have converged on the biotech industry to create the perfect storm, catapulting biotech patent practitioners into murky waters surrounded by unknowns. This interactive session will help you to navigate the political system with an in-depth analysis of the evolving legal standards and changing players including:

• Evaluating the Tafas decision and the impact of the proposed PTO rules on the biotech sector
  • Predicting howTafas will eventually be resolved
  • Determining what the practical application of the new PTO rules will be after Tafas
• Analysis of proposed patent reform legislation and its impact on the industry
• Understanding how the courts are addressing the issue of patent reform in the absence of congressional action
• Discerning the priorities of the Obama administration and the impact on biotech
  • New PTO Commissioner
  • How will the administration help to promote innovation in biotech?
• Reconciling the needs of the biotech industry with the emerging new rules
• Regulatory and Statutory Reexamination Reforms
• Incorporating deferred patent prosecution
• Strategically preparing a long-term plan to account for further reform in opposition to biotech’s goals

To view the conference brochure and register for the event click here.

More and more infringement litigation defendants seek parallel patent reexaminations at the USPTO.  The USPTO ex parte and inter partes reexamination process is explained.  Understand the impact of reexamination on litigation strategy and tactics; cutting-edge issues including collateral estoppel and intervening rights; conflicts between reexamination and court findings, NTP v. RIM and eBay v. MercExchange; and motions for stay based on pending reexamination proceedings.

To learn more about the event, click here.

To learn more about the conference, click here.

 To learn more about the invite visit http://www.law.gmu.edu/events/hottopics/2009 or see the brochure.

To learn more about the conference, click here.

• What are the “value-creating” events/milestones during the drug development process?
• From an implementation perspective, what activities should be performed, and when, to achieve these milestones?
• How can a biopharma company best leverage these milestones in its efforts to raise capital to achieve the next clinical milestone?

To register for the event, click here.

 To learn more about the conference, click here.

• How innovative companies can overcome two major obstacles:
  • Create and protect technologies that are both functionally and economically feasible particularly in industries with a low profit margin like the biofuel industry
  • Navigate relevant technology patents that are issued or pending
• Explore steps that emerging biofuel and other cleantech companies must take in order to avoid the kind of patent problems that have plagued and ultimately destroyed many new innovative companies

To learn more about this panel presentation click here.

To view the conference brochure, click here.

•  What coaching is (and isn’t).
• What Coaching Certification Programs have to offer.
• How coaching has been used (if at all) at our firms.
• Coach Training.
• Getting Management Buy-in.
• Development of Career Coaching Materials.
• Coaching Examples - Those We Coach.

To learn more about the National Adult Education Professional Development Consortium, click here.

The webinar will cover:

• Background of the case and brief analysis of the proposed final rules: 78, 114, 75 & 265
• Analyzing the details, reasoning and nuances of Tafas v. Doll, including:
  • Distinguishing between substantive versus procedural rules
  • Explaining the conflict between Section 120 of the Patent Act and Final Rule 78 limiting continuations
  • Contrasting the court’s reasoning for holding Rule 78 invalid while upholding the rules regarding claims, ESDs, and RCEs  
  • Examining the criteria discussed for the lower court to consider upon remand  
•  Evaluating possible statutory reasons for why Rule 75 could also be under attack
•  What happens next and where do we go from here?

To learn more about the webinar, click here. 
To register for the event, click here.

• Taking advantage of Expired Patents 
• Leveraging the ideas found in International Patents
• Finding Licensing Opportunities of U.S. Patents
• Clearing Products and Designing Around Unexpired U.S. Patents
• Procuring Patents for Core Technologies
• Obtaining Patents for Revolutionary Ideas 
• Obtaining Patents for Evolutionary Ideas
• Using Special Provisions of the Patent Rules

 To learn more about the conference, click here.

Provided bleow is the article and PowerPoint presentation from the conference.

To learn more about the webinar, click here.

 To learn more about the conference, click here.

To learn more about the event, click here.

To learn more about this seminar, click here.

To learn more about the event, click here. 
To view the agenda, click here.

To learn more about the seminar, click here.

To learn more about this conference, click here.

 To view more information on the conference, click here.

• When does IP management become a critical stage for commercialization and investment?
• Challenges impacting the vaccine IP environment through private investment.
• What does it mean to both the investor and investee when engaging in partnerships?

With patents of profitable products set to expire, pharmaceutical companies are incorporating new delivery systems to existing products as an extension strategy. This session explores some of the issues to be aware of during this process.

• The Vanities: Dealing with rankings - Chambers, Supers, Best ofs – Maria Nanis (Dechert)
• Experience Databases: We know we did it, but who did what with whom, when, how and how much do we charge for it anyway? - Vickie Gray (Ober) & Nathan Darling (Van Ness Feldman)
• Client & Industry Service Teams: How they work and how to run them - Ellen Musante (Steptoe)
• RFPs / Proposals / Preferred Provider Surveys: Best practices - Mona Zeiberg (Morgan Lewis) & Suzette Bradbury (Venable)
• Business Plans: Process and Follow Ups  - Tim Delaney (WilmerHale) & Mary Kimber (Patton Boggs)
• Managing Up, Managing Down and Sideways all at the same time - Kelly Stuart (Morrison & Foerster)
• Research:  What's it all about? - Kimberly Bell (Nixon Peabody)
• Going Green: Great idea, how do you do it? - Tammy Mangan (Sterne Kessler)
• PR - How do I get above the fold? - Jonathan Groner (Jenner & Block) & Ellen Katkin (Gilbert Randolph)
• Building a Great Team - Mark Greene (Nixon Peabody)
• CRM Issues & Features - Don’t you just love them? Gail Hageman (Sutherland)
  

 To view the presentation click here.

• When does IP management become a critical stage for commercialization and investment?
• Challenges impacting the vaccine IP environment through private investment.
• What does it mean to both the investor and investee when engaging in partnerships?